Brand Reference: Protonix
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pantoprazole Sodium Delayed-Release RxNorm Concept ID | 40790 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0340 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $28.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.00 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $6.00 / mo | 32 Zero-PHI Verified Patient Logs |
Protonated inside acidic parietal canaliculi (pH < 2) into a reactive sulfenamide that forms covalent disulfide bonds with Cys813 and Cys822 of gastric H+/K+-ATPase—exhibiting the lowest CYP2C19 drug-interaction potential in the PPI class (preferred with clopidogrel).
Across 32 community cost disclosures for Pantoprazole Sodium Delayed-Release (Protonix), cash buyers routing around $28.00 retail markups capture a 82% discount ($5.00/mo benchmark vs $0.0340 NADAC acquisition).
Following administration (20 mg DR PO 30 min before breakfast), Pantoprazole Sodium Delayed-Release achieves 77% enteric tablet bioavailability and 2.5 hours initial; day-4 steady antisecretory plateau onset, governed by a 1 hour plasma / 46 hours covalent pump restoration time terminal half-life through cyp2c19 demethylation followed immediately by cytosolic sulfotransferase conjugation.
Before initiating Pantoprazole Sodium Delayed-Release at 20 mg DR PO 30 min before breakfast, clinical safety checklists rule out rilpivirine co-administration; chronic unmonitored multi-year use without b12/mg2+ audit. Logged tolerability patterns center on rebound hyperacidity if stopped abruptly (26% of reports), bloating (9% of reports), hypomagnesemia (chronic) (8% of reports).
Across 32 verified cash-pay logs, Pantoprazole Sodium Delayed-Release achieves a 86.30% Worth-It rating with out-of-pocket spend averaging $6.00/mo versus $28.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 20 mg DR PO 30 min before breakfast for Pantoprazole Sodium Delayed-Release; monthly out-of-pocket dropped to $4.50 compared with $28.00 retail.
Completed 10 weeks on Pantoprazole Sodium Delayed-Release (40 mg DR PO 30 min pre-breakfast x 4–8 weeks). Zero notable side effects on steady dosing.
Consistent biomarker response on 20 mg DR PO 30 min before breakfast Pantoprazole Sodium Delayed-Release sourced via Compounding ($5.80/mo cash pay without insurance prior authorization).